Cited by 229Treatment of Major DepressionTryptophan and brain disordersNeurotransmitter Receptor Influence on Behavior

Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study

Mendlewicz, Julien, Kriwin, Philippe, Oswald, Pierre, Souery, Daniel, Alboni, Silvia, Brunello, Nicoletta·2006·International Clinical Psychopharmacology

Abstract

Based on our preclinical data showing a potential accelerating effect of acetylsalicylic acid (ASA) in combination with fluoxetine in an animal model of depression, we examined the effect of ASA augmentation therapy on selective reuptake inhibitors (SSRI) in major depressed non-responder patients. Twenty-four non-responder patients having received at least 4 weeks of an adequate SSRI treatment were included in a pilot open-label study. Participants were treated openly during 4 weeks with 160 mg/day ASA in addition to their current antidepressant treatment. The combination SSRI-ASA was associated with a response rate of 52.4%. Remission was achieved in 43% of the total sample and 82% of the responder sample. In the responder group, a significant improvement was observed within week 1 (mean Hamilton Depression Rating Scale-21 items at day 0=29.3+/-4.5, at day 7=14.0+/-4.1; P<0.0001) and remained sustained until day 28. Despite limitations due to the open nature of this study, our preliminary results confirm our preclinical findings and are in favour of an accelerating effect of ASA in combination with SSRIs in the treatment of major depression. Potential physiological and biochemical mechanisms may involve an anti-inflammatory and/or neurotrophic effect.

Integrity signals

Registry

Crossref · 10.1097/00004850-200607000-00005

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In that open-label study, responders to combined SSRI-acetylsalicylic acid treatment had HRSD scores decrease from 29.3 at Day 0 to 8.4 at Day 28, a reduction of 20.9 HRSD points.

    “patients who were considered responders to the combined SSRI-acetylsalicylic acid treatment saw their HRSD scores decrease from 29.3 at Day 0 to 8.4 at Day 28 of the study, which was a reduction of 20.9 HRSD points”
  • In an open-label study of treatment-resistant depression, 52.4% of depressed individuals treated with acetylsalicylic acid in addition to an SSRI were considered responders after not responding to a first SSRI treatment.

    “52.4% of depressed individuals who were treated with acetylsalicylic acid (i.e., aspirin) in addition to receiving a selective reuptake inhibitor (SSRI) were considered responders after having not responded to a first SSRI treatment.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N.
Affiliations
  • Université Libre de Bruxelles (BE)
  • University of Modena and Reggio Emilia (IT)
Corresponding author
Mendlewicz, Julien
Venue
International Clinical Psychopharmacology
Published
2006-07
Volume
21
Issue
4
Pages
227-231
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2029123366
Cited by
229
References
6
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 16 · 2019: 13 · 2018: 21 · 2017: 17 · 2016: 11 · 2015: 16 · 2014: 21 · 2013: 23 · 2012: 14
FWCI
2.93
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
aspirin, antidepressant augmentation, major depressive disorder, selective serotonin reuptake inhibitors, fluoxetine, treatment-resistant depression, onset of action, anti-inflammatory activity, neurotrophic effects, remission
MeSH terms
Adult, Anti-Inflammatory Agents, Antidepressive Agents, Aspirin, Depressive Disorder, Major, Major Depressive Disorder, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review